Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 71fludarabine phosphate 63Busulfan 47Peripheral Blood Stem Cell Transplantation 44Tacrolimus 41Mycophenolic Acid 37Antilymphocyte Serum 37Filgrastim 32Cyclosporine 30Melphalan 29Whole-Body Irradiation 28Radiotherapy 28fludarabine 26Methotrexate 23Methylprednisolone 18Etoposide 18Cord Blood Stem Cell Transplantation 17Rituximab 13Alemtuzumab 13Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 10Sirolimus 9Thiotepa 8Cytarabine 8sargramostim 7Prednisone 7Epoetin Alfa 7Flow Cytometry 6thymoglobulin 5Trimethoprim, Sulfamethoxazole Drug Combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × siplizumab × Plasma cell × Clear all
NCT00113646 2018-03-16

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Massachusetts General Hospital

Phase 2 Terminated
14 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡